Report Overview

The Australian Lysosomal Storage Disorder Therapeutics Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

LSDs usually are caused by a deficiency of a single lysosomal enzyme or protein, which results in a build-up of a lipid (a type of fat) or sugar in the lysosome. There are many lysosomal enzymes and they each work in sequence with each other to break down lipids and sugars into simpler forms for removal from the cell. A deficiency in the function of one enzyme means that it cannot do its job; it also means that the enzymes that follow in the sequence cannot do theirs: the process of breaking down and recycling lipids and sugars stops, and they remain stored in the lysosomes of each cell. This affects normal cell function. A simple analogy to illustrate what happens in the cell is to think of a kitchen in which its rubbish is never taken out.

In Australia, the incidence of LSDs as a group was calculated to be 1 in 7,700, ranging from 1 in 57,000 for Gaucher disease to as low as 1 in 4.2 million for sialidosis. However, the prevalence of Fabry disease, Gaucher disease, Pompe disease, and Tay-Sachs disease is estimated at 11.7%, 5.7%, 14.6%, 20.6%, respectively, in Australia.



Market Drivers

Growing public awareness of rare Lysosomal Storage Disorders, increasing research and development for diagnosis and drug development for treatment of Lysosomal Disorders, and increasing incidences of lysosomal diseases are key market drivers. The market is hampered by the high cost of treatment.